Date：29 July (Friday)
Time: 15:40 – 18:00 (GMT+8)
Head, Biopharma Digital Health R&D
Matt Bonam is currently Head of Digital Health for BioPharmaceuticals R&D. In Digital Health R&D, the team are transforming R&D through digital, data and AI to deliver new digital health solutions to improve outcomes and experience for patients, and to partner with colleagues globally to reimagine healthcare delivery. He leads a diverse team focusing on accelerating and differentiating our clinical development programmes through digital health solutions and on the development of digital therapeutics. A recent example is the implementation and scale up of Unify, our new clinical study support platform which is now part of several of our trials around the world. Unify is enabling us to improve remote patient data collection, as well as supporting clinical trial accessibility, diversity and retention. Matt and his team also work actively with the R&D therapy area teams to explore approaches that can combine our innovative new treatments with evidence-based digital health solutions, such as digital biomarkers, digital diagnostics and digital therapeutics.
A chemist by training, Matt has been part of the pharmaceutical industry for over 25 years. He has been at AstraZeneca for over 20 years in various roles across R&D and Operations, including as Founder and Head of the Intelligent Pharmaceuticals group, Project Director in Chemistry, Manufacturing and Controls (CMC) and Project Lead roles across different therapy areas.
Digital transformation is a key focus in clinical trial development during the post-pandemic era. Unify, a digital patient solution developed by AstraZeneca, makes clinical trials easier and gives everyone involved more clarity, flexibility and peace of mind. It will help improve all participants clinical trial experience and outcomes by relieving many of the administrative burdens of the trial process and making the trials fit better into the patients’ life.
Enhance participant experience - Deliver an optimal clinical trial participant experience before, during and after the trial.
Improve outcomes - Help patients to get better treatment outcomes.
Increase participation for faster and smaller trials - Increase the numbers of patients who complete a study by utilising a common platform to recruit, engage and retain participants in our studies, enabling faster trial completion and a reduced size of trial required to study a specific concept.
Improve adherence - Improve adherence to study procedures for all participants through digital coaching and remote data collection.
Faster adverse event management - Reduce study deviations and reduce the time it takes for an event to be managed through real time data analysis.
Generate higher quality data for faster decision making - Through increased frequency of sampling, create higher quality scientific value and enable novel endpoints. This will provide the foundation for advanced analytics and planning for predictive decision making.